AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3006449 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with Htz
Number of subjects: 24
Study 3006449 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment regimens
Number of subjects: 24
Study 30459053 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 16 weeks (EXER)
Number of subjects: 160
Study 30459053 — intervention group
Group type: COMPARATOR
Intervention: Control sedentary group (CONT)
Number of subjects: 160
Study 27009044 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 81
Study 27009044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 24238118 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training in communication skills and use of a patient booklet
Number of subjects: 0
Study 24238118 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training in use of the C-reactive protein (CRP) test
Number of subjects: 0
Study 24238118 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training in both communication skills and use of a patient booklet
Number of subjects: 0
Study 24238118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21362103 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 89
Study 21362103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19592202 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted insulin protocol (CAIP)
Number of subjects: 167
Study 19592202 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuven protocol
Number of subjects: 167
Study 19592202 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 167
Study 17964390 — intervention group
Group type: EXPERIMENTAL
Intervention: 213 nm solid-state laser
Number of subjects: 30
Study 17964390 — intervention group
Group type: COMPARATOR
Intervention: 193 nm excimer laser
Number of subjects: 30
Study 15118193 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted fruit juice (FJ, 10.4% total carbohydrate, 489 mosmol/L, pH= 3.2)
Number of subjects: 40
Study 15118193 — intervention group
Group type: COMPARATOR
Intervention: No-fluid trial
Number of subjects: 40
Study 15118193 — intervention group
Group type: COMPARATOR
Intervention: Flavored water (FW, no carbohydrate, osmolality = 48 mosmol/L, pH = 3.3)
Number of subjects: 40
Study 15118193 — intervention group
Group type: COMPARATOR
Intervention: Sports drink (SD, 6% total carbohydrate, 295 mosmol/L, pH = 3.3)
Number of subjects: 40
Study 11172512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 3.75 mg with fentanyl 25 microg
Number of subjects: 40
Study 11172512 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric lidocaine 30 mg with fentanyl 25 microg
Number of subjects: 40
Study 9436001 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of family education programs (group consultation)
Number of subjects: 0
Study 9436001 — intervention group
Group type: COMPARATOR
Intervention: Conventional group workshop model
Number of subjects: 0
Study 8099789 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 45
Study 8099789 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo (E)
Number of subjects: 45
Study 8099789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Treatment (CT)
Number of subjects: 45
Study 8099789 — intervention group
Group type: COMPARATOR
Intervention: AR vs CT
Number of subjects: 45
Study 3578568 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus professional psychotherapy
Number of subjects: 93
Study 3578568 — intervention group
Group type: COMPARATOR
Intervention: Paraprofessional drug counseling
Number of subjects: 93
Study 30562785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX) 2 μg/kg
Number of subjects: 60
Study 30562785 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (0.9% saline) 0.02 mL/kg
Number of subjects: 60
Study 27262908 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough pathologic examination of lymph nodes (mean number of mediastinal lymph nodes examined: 13.5 for pN0, 13.1 for pN1, 17.1 for pN2)
Number of subjects: 513
Study 27262908 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased examination of mediastinal and non-hilar N1 lymph nodes
Number of subjects: 513
Study 24254339 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation-assisted stone extraction (group A)
Number of subjects: 462
Study 24254339 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST) (group B)
Number of subjects: 462
Study 22414688 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 0, 100, 250, and 500 g
Number of subjects: 32
Study 22414688 — intervention group
Group type: EXPERIMENTAL
Intervention: Red beetroot-enriched bread (100 g)
Number of subjects: 32
Study 22414688 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary nitrate/nitrite (NO(x)) after BJ consumption
Number of subjects: 32
Study 22414688 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary nitrate/nitrite (NO(x)) after red beetroot-enriched bread ingestion
Number of subjects: 32
Study 22414688 — intervention group
Group type: COMPARATOR
Intervention: Control bread (0 g beetroot)
Number of subjects: 32
Study 21079163 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered preservative‐free acidified solution in saline nasal spray
Number of subjects: 20
Study 21079163 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride‐containing saline nasal spray
Number of subjects: 20
Study 21079163 — intervention group
Group type: COMPARATOR
Intervention: Both nasal spray solutions
Number of subjects: 20
Study 18946193 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 13
Study 18946193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15924527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 98
Study 15924527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12847284 — intervention group
Group type: EXPERIMENTAL
Intervention: Live recombinant canarypox ALVAC-HIV vaccine with or without rgp120/SF-2
Number of subjects: 12
Study 12847284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10439770 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 2.5 mg
Number of subjects: 120
Study 10439770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 120
Study 8537681 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 10(7) TCID50 of live, attenuated cold‐adapted influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine
Number of subjects: 0
Study 8537681 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 10(7) TCID50 of ca influenza virus
Number of subjects: 0
Study 1925862 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment followed by radiation therapy (102 patients), total dose of 45 to 55 Grays delivered to specific areas.
Number of subjects: 221
Study 1925862 — intervention group
Group type: COMPARATOR
Intervention: Isolated surgical treatment (119 patients).
Number of subjects: 221
Study 1925862 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment followed by radiation therapy (102 patients).
Number of subjects: 221
Study 6958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms daily for 4 months
Number of subjects: 19
Study 6958488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 19
Study 6958488 — intervention group
Group type: COMPARATOR
Intervention: Budesonide and Placebo
Number of subjects: 19
Study 31262105 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Sleep Questionnaire (PSQ)
Number of subjects: 11420
Study 31262105 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups comparison
Number of subjects: 11420
Study 31262105 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 11420
Study 31262105 — intervention group
Group type: EXPERIMENTAL
Intervention: Various sleep-related factors
Number of subjects: 11420
Study 29182350 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 4737
Study 25257982 — intervention group
Group type: EXPERIMENTAL
Intervention: Active waterpipe tobacco (preferred brand/flavor)
Number of subjects: 80
Study 25257982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavor‐matched tobacco‐free waterpipe product)
Number of subjects: 80
Study 25257982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Active and Placebo
Number of subjects: 80
Study 24401041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (Antenatal Asthma Management Service)
Number of subjects: 378
Study 24401041 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Group
Number of subjects: 378
Study 22252927 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) - 24 sessions over 12 weeks, twice weekly.
Number of subjects: 47
Study 19463151 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 (100 IU/kg body weight, intravenous, three-times-weekly for four weeks)
Number of subjects: 80
Study 19463151 — intervention group
Group type: COMPARATOR
Intervention: Comparator epoetin alfa (100 IU/kg body weight, intravenous, three-times-weekly for four weeks)
Number of subjects: 80
Study 19463151 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 and comparator epoetin alfa
Number of subjects: 80
Study 17470000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sellers (participants given a good to sell)
Number of subjects: 0
Study 17470000 — intervention group
Group type: COMPARATOR
Intervention: Choosers (participants given a choice between a good and cash)
Number of subjects: 0
Study 17470000 — intervention group
Group type: EXPERIMENTAL
Intervention: Altering the order of queries posed
Number of subjects: 0
Study 15023749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic mapping and sentinel lymph node (SLN) biopsy
Number of subjects: 0
Study 15023749 — intervention group
Group type: EXPERIMENTAL
Intervention: Very sensitive assays based on reverse transcriptase polymerase chain reaction technology
Number of subjects: 0
Study 15023749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrastaging by examining SLNs, peripheral blood, and bone marrow
Number of subjects: 0
Study 15023749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic mapping procedure
Number of subjects: 0
Study 12145433 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 155
Study 12145433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 9795453 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-ml oral sodium phosphate (NaP)
Number of subjects: 46
Study 9795453 — intervention group
Group type: COMPARATOR
Intervention: X-Prep
Number of subjects: 46
Study 9795453 — intervention group
Group type: COMPARATOR
Intervention: 45-ml oral sodium phosphate (NaP)
Number of subjects: 46
Study 7709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg TID)
Number of subjects: 50
Study 7709404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7709404 — intervention group
Group type: COMPARATOR
Intervention: Picotamide vs Placebo
Number of subjects: 50
Study 7709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide
Number of subjects: 50
Study 2796621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 2 mg/kg iv
Number of subjects: 80
Study 2796621 — intervention group
Group type: COMPARATOR
Intervention: Physostigmine 1 mg iv and naloxone 0.4 mg im
Number of subjects: 80
Study 66567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (nocturnal administration)
Number of subjects: 0
Study 66567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (continued administration for 1 year)
Number of subjects: 0
Study 66567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (cessation of treatment)
Number of subjects: 0
Study 66567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (repeated short courses for 1 month)
Number of subjects: 0
Study 31475495 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (Climen, 1 tablet/d for 21 days)
Number of subjects: 100
Study 31475495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (manual stimulation of specific points from day 8 to 15 of menstruation, once daily for 3 cycles)
Number of subjects: 100
Study 31475495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (acupuncture + medication)
Number of subjects: 100
Study 31475495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 31475495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment vs Acupuncture
Number of subjects: 100
Study 31475495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment vs Medication
Number of subjects: 100
Study 31475495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Medication
Number of subjects: 100
Study 28922018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 20
Study 28922018 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 20
Study 25914961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise program (90 minutes or more of low to moderate aerobic, resistance, core stability, and balance exercise per week for 12 weeks)
Number of subjects: 30
Study 25914961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 30
Study 23302981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric volume using Right lat CSA measurement
Number of subjects: 108
Study 23302981 — intervention group
Group type: COMPARATOR
Intervention: Previous models of ultrasound gastric volume assessment
Number of subjects: 108
Study 21672493 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone, 20‐80 mg twice a day
Number of subjects: 298
Study 21672493 — intervention group
Group type: COMPARATOR
Intervention: placebo twice a day
Number of subjects: 298
Study 21672493 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 298
Study 21672493 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 298
Study 18636953 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral MenB outer membrane vesicle vaccine
Number of subjects: 21
Study 18636953 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated subjects)
Number of subjects: 21
Study 16882446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 0
Study 16882446 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccination
Number of subjects: 0
Study 16882446 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae (Hib) vaccination
Number of subjects: 0
Study 12971704 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning exercises on hardness discrimination using three different levels of hardness of a rubber sponge for 10 days
Number of subjects: 28
Study 12971704 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 28
Study 11078240 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.2 to 3.6 microg/kg/min)
Number of subjects: 10
Study 11078240 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 10
Study 11078240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8658295 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 0
Study 8658295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1419223 — intervention group
Group type: COMPARATOR
Intervention: Astemizole 5 mg daily for 2 weeks followed by increasing doses (5, 10, 20, 40 mg per day)
Number of subjects: 69
Study 1419223 — intervention group
Group type: COMPARATOR
Intervention: Astemizole 10 mg daily for 12 weeks
Number of subjects: 69
Study 1419223 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole plus DMA
Number of subjects: 69
Study 3976329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal nerve block (DNB)
Number of subjects: 50
Study 3976329 — intervention group
Group type: COMPARATOR
Intervention: Caudal analgesia
Number of subjects: 50
Study 30643081 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) - esomeprazole
Number of subjects: 40
Study 30643081 — intervention group
Group type: COMPARATOR
Intervention: Histamine H2 receptor antagonist (H2 blocker) - famotidine
Number of subjects: 40
Study 30157577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 60
Study 30157577 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (NP)
Number of subjects: 60
Study 27814722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention
Number of subjects: 1370
Study 27814722 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1370
Study 24183511 — intervention group
Group type: EXPERIMENTAL
Intervention: BioOss® mixed with autogenous bone marrow concentrate
Number of subjects: 12
Study 24183511 — intervention group
Group type: COMPARATOR
Intervention: BioOss® mixed with autogenous bone
Number of subjects: 12
Study 24183511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study 22249480 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy
Number of subjects: 42
Study 22249480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 42
Study 22249480 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy and Intubating laryngeal mask airway
Number of subjects: 42
Study 20077670 — intervention group
Group type: COMPARATOR
Intervention: Domestic split influenza virus vaccine
Number of subjects: 12
Study 20077670 — intervention group
Group type: COMPARATOR
Intervention: Imported split influenza virus vaccine
Number of subjects: 12
Study 17341027 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg flucloxacillin capsules
Number of subjects: 20
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple walking task
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-motor task
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cognitive task
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple task
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (Brixton test)
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fatigue
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 30
Study 15468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance (Berg Balance Scale)
Number of subjects: 30
Study 11226790 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive multifocal intraocular lens (MIOL)
Number of subjects: 231
Study 11226790 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lens (IOL)
Number of subjects: 231
Study 9742717 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent priming trials
Number of subjects: 0
Study 9742717 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent priming trials
Number of subjects: 0
Study 9742717 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming effects
Number of subjects: 0
Study 9742717 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis of prime perceptibility
Number of subjects: 0
Study 7761016 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA): propofol + fentanyl + pancuronio bromide
Number of subjects: 40
Study 7761016 — intervention group
Group type: COMPARATOR
Intervention: Balanced Narcosis: TPS + Isoflurane + Pancuronio bromide
Number of subjects: 40
Study 3260794 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride 16 mmol in 10 ml of water
Number of subjects: 20
Study 3260794 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of water alone (control group)
Number of subjects: 20
Study 29878340 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg IV infusion
Number of subjects: 88
Study 29878340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 28157100 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg for 6 weeks and 10 mg for 18 weeks)
Number of subjects: 313
Study 28157100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 28157100 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 313
Study 26212528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 219
Study 26212528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 24147138 — intervention group
Group type: EXPERIMENTAL
Intervention: Inquiry-based learning pedagogy training
Number of subjects: 52
Study 24147138 — intervention group
Group type: COMPARATOR
Intervention: General instructional 'best practices' training
Number of subjects: 52
Study 21392951 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy (using increased expiratory acceleration)
Number of subjects: 0
Study 17571933 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 34
Study 17571933 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser‐assisted technique
Number of subjects: 34
Study 17571933 — intervention group
Group type: COMPARATOR
Intervention: Erbium:YAG lasers laser‐assisted technique
Number of subjects: 34
Study 15370722 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 21
Study 15370722 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 21